Testing a Blood Test to Detect Early Pancreatic Cancer
Tests a noninvasive blood-based exosome marker test for early pancreatic ductal adenocarcinoma in adults.
Plain-language title generated from the registry record
Registry title: Pancreatic Cancer Detection Consortium
Key facts
- Where
- Nagoya, JapanSee the site
Where in Japan
- Nagoya UniversityNagoya, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- City of Hope Medical Center
- Trial code
- NCT06388967
- Record updated
- 28 September 2026
- Original description
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.Read full original descriptionShow less
Early Detection of Pancreatic Cancer: Prospective Study
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Inclusion: Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition); Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment; Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls).
Exclusion: Lack of written informed consent.